


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of treating, preventing or managing macular degeneration, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of ~~a selective cytokine inhibitory drug~~, cyclopropyl-N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisindoline-4-yl]carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate, ~~or stereoisomer~~ thereof.

2. (Previously presented) The method of claim 1, which further comprises administering to the patient a therapeutically or prophylactically effective amount of a second active agent.

3. (Previously presented) The method of claim 2, wherein the second active agent is a steroid, a light sensitizer, an integrin, an antioxidant, an interferon, a xanthine derivative, a growth hormone, a neutrotrophic factor, a regulator of neovascularization, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound or an antiangiogenesis compound.

4. (Previously presented) The method of claim 2, wherein the second active agent is thalidomide, verteporfin, purlytin, an angiostatic steroid, rhuFab, interferon-2 α or pentoxifylline, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


5. (Currently amended) The method of claim 4 3, wherein the antiangiogenesis compound is thalidomide.

6. (Previously presented) The method of claim 1, wherein the macular degeneration is wet macular degeneration, dry macular degeneration, age-related macular degeneration, age-related maculopathy, choroidal neovascularisation, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, or macular damaging condition.

7. (Previously presented) The method of claim 1, wherein the ~~selective cytokine inhibitory drug~~ compound is stereomerically pure.

8 to 17. (Canceled).

18. (Currently amended) A method of treating, preventing or managing macular degeneration, which comprises administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of ~~a selective cytokine inhibitory drug~~, cyclopropyl-N-(2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisindoline-4-yl)carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate, ~~or stereoisomer~~ thereof, before, during or after surgical intervention directed at reducing or avoiding a symptom of macular degeneration in the patient.

19. (Currently amended) The method of claim ~~17~~ 18, wherein the surgical intervention is light therapy, laser therapy, radiation therapy, retinal pigment epithelium transplantation, or foveal translocation.

20 to 22. (Canceled)